Olga Belotserkovskaya, MD
Psychiatry · Bessemer, ALNPI 1144310111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 312 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$928
- Alkermes, Inc.$601
- Teva Pharmaceuticals USA, Inc.$527
- Avanir Pharmaceuticals, Inc.$453
- Lilly USA, LLC$440
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$429
- plus $3K from 19 others
What the payments were for
- Food & beverage$5,94398%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $928 |
| Alkermes, Inc. | 27 | $601 |
| Teva Pharmaceuticals USA, Inc. | 22 | $527 |
| Avanir Pharmaceuticals, Inc. | 31 | $453 |
| Lilly USA, LLC | 13 | $440 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $429 |
| Axsome Therapeutics, Inc. | 12 | $354 |
| Johnson & Johnson | 18 | $325 |
| Indivior Inc. | 16 | $262 |
| Vanda Pharmaceuticals Inc. | 9 | $228 |
| Sunovion Pharmaceuticals Inc. | 2 | $218 |
| Otsuka America Pharmaceutical, Inc. | 13 | $212 |
| Bausch Health US, LLC | 13 | $204 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| Biogen | 5 | $105 |
| Acadia Pharmaceuticals Inc | 5 | $100 |
| Eisai Inc. | 8 | $100 |
| Jazz Pharmaceuticals Inc. | 2 | $95 |
| Neurocrine Biosciences, Inc. | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Lundbeck LLC | 3 | $60 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $55 |
| Almatica Pharma LLC | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,039 in reported general payments places this provider in the 85th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 11 | $82,402 |
| PerserisRisperidone | 24 | $59,387 |
| NuplazidPimavanserin Tartrate | 11 | $56,011 |
| Abilify MaintenaAripiprazole | 13 | $41,680 |
| VraylarCariprazine Hcl | 27 | $38,794 |
| NuedextaDextromethorphan Hbr/Quinidine | 29 | $36,252 |
| CaplytaLumateperone Tosylate | 19 | $32,510 |
| Risperdal ConstaRisperidone Microspheres | 29 | $25,589 |
| Lurasidone Hcl | 47 | $19,850 |
| TrintellixVortioxetine Hydrobromide | 20 | $16,350 |
| Modafinil | 160 | $13,392 |
| Quetiapine Fumarate | 577 | $11,960 |
| Aripiprazole | 114 | $9,046 |
| Duloxetine Hcl | 182 | $6,210 |
| Clonazepam | 578 | $4,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Risperdal Consta | $325 | $107,99140 claims |
| Indivior Inc.Perseris | $262 | $59,38724 claims |
| Acadia Pharmaceuticals IncNuplazid | $100 | $56,01111 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $212 | $41,68013 claims |
| AbbVieVraylar | $928 | $38,79427 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $453 | $36,25229 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $429 | $32,51019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $69 | $16,35020 claims |
| Lilly USA, LLCOlanzapine | $440 | $3,475181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Bessemer
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
- Richard SheltonBirmingham$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.